跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLUCOVISION (CITRATE) - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
GLUCOVISION (CITRATE)
Authorized
STANDARD
GLUCOVISION (CITRATE)
Centre For Probe Development And Commercialization
🇨🇦 Health Canada
Approval Date
Feb 5, 2026
Approval ID
7ed945e4ce733f1c
Company
Centre For Probe Development And Commercialization
Type
Standard
Approval Details
Approval Id
7ed945e4ce733f1c
Drug Approval Canada Name
GLUCOVISION (CITRATE)
Product Name
GLUCOVISION (CITRATE)
Status
Cancelled Post Market
Drug Class
Radiopharmaceutical
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule C
Ahfs
36:68.00
Atc Original
V09IX04 FLUDEOXYGLUCOSE (18F)
Aig Number
0152591020
Company Name
Centre For Probe Development And Commercialization
Company Address
175 Longwood Rd. S., Suite 301a Mcmaster Innovation Park Hamilton Ontario Canada L8P 0A1
Company Detail Path
/organization/centre-for-probe-development-and-commercialization
Company Information
Pharmaceutical Company Name
Centre For Probe Development And Commercialization
Country Name
Canada
Province Name
Ontario
City Name
hamilton,ontario,country_ca
Address
1-1280 Main St W
Website
http://www.imagingprobes.ca/
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Feb 5, 2026
Approval ID
7ed945e4ce733f1c
Type
Standard
Back to Health Canada Approvals